Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Massachusetts Department of Public Health, Boston, Massachusetts, USA.
J Int AIDS Soc. 2023 Jan;26(1):e26040. doi: 10.1002/jia2.26040.
Data-to-care programmes utilize surveillance data to identify persons who are out of HIV care, re-engage them in care and improve HIV care outcomes. We assess the costs and cost-effectiveness of re-engagement in an HIV care intervention in the United States.
The Cooperative Re-engagement Control Trial (CoRECT) employed a data-to-care collaborative model between health departments and HIV care providers, August 2016-July 2018. The health departments in Connecticut (CT), Massachusetts (MA) and Philadelphia (PHL) collaborated with HIV clinics to identify newly out-of-care patients and randomize them to receive usual linkage and engagement in care services (standard-of-care control arm) or health department-initiated active re-engagement services (intervention arm). We used a microcosting approach to identify the activities and resources involved in the CoRECT intervention, separate from the standard-of-care, and quantified the costs. The cost data were collected at the start-up and recurrent phases of the trial to incorporate potential variation in the intervention costs. The costs were estimated from the healthcare provider perspective.
The CoRECT trial in CT, MA and PHL randomly assigned on average 327, 316 and 305 participants per year either to the intervention arm (n = 166, 159 and 155) or the standard-of-care arm (n = 161, 157 and 150), respectively. Of those randomized, the number of participants re-engaged in care within 90 days in the intervention and standard-of-care arms was 85 and 70 in CT, 84 and 70 in MA, and 98 and 67 in PHL. The additional number of participants re-engaged in care in the intervention arm compared with those in the standard-of-care arm was 15 (CT), 14 (MA) and 31 (PHL). We estimated the annual total cost of the CoRECT intervention at $490,040 in CT, $473,297 in MA and $439,237 in PHL. The average cost per participant enrolled was $2952, $2977 and $2834 and the average cost per participant re-engaged in care was $5765, $5634 and $4482. We estimated an incremental cost per participant re-engaged in care at $32,669 (CT), $33,807 (MA) and $14,169 (PHL).
The costs of the CoRECT intervention that identified newly out-of-care patients and re-engaged them in HIV care are comparable with other similar interventions, suggesting a potential for its cost-effectiveness in the US context.
数据到护理计划利用监测数据识别出已经脱离 HIV 护理的人,使他们重新接受护理,并改善 HIV 护理结果。我们评估了在美国重新参与 HIV 护理干预的成本和成本效益。
合作重新参与控制试验(CoRECT)于 2016 年 8 月至 2018 年 7 月期间在卫生部门和 HIV 护理提供者之间采用了数据到护理的合作模式。康涅狄格州(CT)、马萨诸塞州(MA)和费城(PHL)的卫生部门与 HIV 诊所合作,确定新脱离护理的患者,并将他们随机分配到接受常规链接和护理服务(标准护理对照组)或卫生部门发起的主动重新参与服务(干预组)。我们采用微观成本法来确定 CoRECT 干预措施中涉及的活动和资源,这些活动和资源与标准护理分开,并量化了成本。成本数据是在试验的启动和经常性阶段收集的,以纳入干预成本的潜在变化。成本从医疗保健提供者的角度进行估算。
在 CT、MA 和 PHL 进行的 CoRECT 试验平均每年随机分配 327、316 和 305 名参与者至干预组(n=166、159 和 155)或标准护理组(n=161、157 和 150)。在随机分配的参与者中,在 90 天内重新接受护理的参与者数量,在干预组和标准护理组中,CT 为 85 和 70,MA 为 84 和 70,PHL 为 98 和 67。与标准护理组相比,干预组重新接受护理的参与者人数增加了 15(CT)、14(MA)和 31(PHL)。我们估计 CoRECT 干预措施的年度总成本在 CT 为 490040 美元,在 MA 为 473297 美元,在 PHL 为 439237 美元。每个入组参与者的平均成本为 2952 美元、2977 美元和 2834 美元,每个重新接受护理的参与者的平均成本为 5765 美元、5634 美元和 4482 美元。我们估计每个重新接受护理的参与者的增量成本为 32669 美元(CT)、33807 美元(MA)和 14169 美元(PHL)。
识别新脱离 HIV 护理的患者并重新使他们接受 HIV 护理的 CoRECT 干预措施的成本与其他类似干预措施相当,这表明该干预措施在美国有潜在的成本效益。